Identifying biomarkers for HIV-related lymphoma in Malawi and South Africa
Official title: Project 3: Tumor-associated biomarkers for HIV-associated Diffuse Large B-cell Lymphoma in Malawi and South Africa
Funded at Univ of North Carolina Chapel Hill · NIH-10891547 · Data updated 2026-11-12
This study is looking at how certain markers in tumors can help doctors better diagnose and treat HIV-related lymphoma in patients in Malawi and South Africa, aiming to improve care for those facing this challenge.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 13, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $233,557 |
| NIH project number | 5U54CA254564-05 |
| Project ID | NIH-10891547 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HIV-associated Diffuse Large B-cell Lymphoma in Malawi or South Africa.
✕Less likely to help
Patients who do not have HIV or are not diagnosed with Diffuse Large B-cell Lymphoma may not benefit from this research.
What this research studies
This research focuses on understanding how certain tumor-associated biomarkers can improve the diagnosis and treatment of HIV-associated Diffuse Large B-cell Lymphoma (DLBCL) in Malawi and South Africa. By studying a cohort of patients, the research aims to identify biological differences in DLBCL that occur in HIV-infected individuals compared to those who are immunocompetent. The approach includes analyzing the tumor microenvironment and using regionally generated biomarkers to enhance patient outcomes. This work seeks to address the unique challenges faced by patients in sub-Saharan Africa, where the incidence of lymphoma is rising due to high rates of HIV infection.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment strategies for patients with HIV-associated lymphoma, ultimately enhancing survival rates.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for various cancers, suggesting that this approach could yield valuable insights for HIV-associated lymphoma as well.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Fedoriw, Yuri — Univ of North Carolina Chapel Hill
- Study coordinator: Fedoriw, Yuri
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.